SCHEMBL3563288

SCHEMBL3563288

Cc1ccc(F)cc1S(=O)(=O)Nc1ccccc1CCCc1ccc(C(=O)O)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 7/20 0.74
RAD52 P43351 1/20 0.53
HDAC3 O15379 1/20 0.46
HDAC2 Q92769 1/20 0.46
NCOR2 Q9Y618 1/20 0.46
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
LMNA P02545 1/20 0.46
ALOX12 P18054 1/20 0.46
PTGER1 P34995 1/20 0.44
PTGER4 P35408 1/20 0.44
PTGER3 P43115 1/20 0.44
PTGER2 P43116 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
IDH1 O75874 2/20 0.43
TRIM24 O15164 1/20 0.43
BRD1 O95696 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3558027 0.95 SLC16A3 (0.81) SLC16A3RAD52HDAC3HDAC2NCOR2
SCHEMBL3561507 0.90 SLC16A3 (0.91) SLC16A3RAD52ALDH1A1SMN1; SMN2LMNA
SCHEMBL3558218 0.88 SLC16A3 (0.57) SLC16A3HDAC3HDAC2NCOR2SMN1; SMN2
SCHEMBL3553938 0.86 SLC16A3 (0.71) SLC16A3RAD52ALDH1A1MEN1KMT2A
SCHEMBL3553499 0.85 SLC16A3 (1.00) SLC16A3RAD52HDAC3HDAC2NCOR2
SCHEMBL3556182 0.84 SLC16A3 (0.68) SLC16A3HDAC3HDAC2NCOR2PTGER1
SCHEMBL3553525 0.83 ALDH1A1 (0.60) SLC16A3RAD52ALDH1A1SMN1; SMN2MEN1
SCHEMBL3559742 0.83 SLC16A3 (0.62) SLC16A3HDAC3HDAC2NCOR2MEN1
SCHEMBL3566257 0.83 SLC16A3 (0.76) SLC16A3RAD52ALDH1A1MEN1KMT2A
SCHEMBL3556525 0.83 SLC16A3 (0.64) SLC16A3SMN1; SMN2PTGER1PTGER4PTGER3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 SLC16A3 425/4885RAD52 4737/4885HDAC3 3383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.